版本:
中国

BRIEF-UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study

Oct 13 Biomarin Pharmaceutical Inc

* UK regulatory agency approves continued enrollment in Biomarin phase 1/2 study of BMN 270 in Hemophilia a

* Biomarin Pharmaceutical Inc - Biomarin intends to resume enrollment in phase i/2 study before end of 2016

* Biomarin Pharmaceutical Inc - Safety and efficacy data from these patients will inform phase 2B study planned to begin in second half of 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐